Nephrocare Health IPO worth ₹871.05 Cr will open for subscription from 10 Dec to 12 Dec 2025. Nephrocare Health allotment is expected on 15 Dec and shares are likely to be listed on BSE & NSE on 17 Dec. Price band for the IPO is set between ₹438 to ₹460 per share and Nephrocare Health GMP today stands flat.
Nephrocare Health IPO GMP Live Rates Day by Day
Nephrocare Health IPO GMP today (9th Dec 2025) stands at 0%. GMP values change daily and we’ll keep you updated with the latest figures.
GMP figures are for news purposes only. We neither trade nor recommend trading in the grey market.
| GMP Date | IPO Price | GMP | Estimated Listing Price | Estimated Profit |
|---|---|---|---|---|
| 12-12-2025 | ₹ 460 | ₹ 11.5 | ₹471.5 (2.50%) | ₹ 368 |
| 11-12-2025 | ₹ 460 | ₹ 11.5 | ₹471.5 (2.50%) | ₹ 368 |
| 10-12-2025 | ₹ 460 | ₹ 20 | ₹480 (4.35%) | ₹ 640 |
| 09-12-2025 | ₹ 460 | ₹ 0 | ₹460 (0%) | ₹ 0 |
Nephrocare Health IPO Details
- Nephrocare Health’s IPO is worth ₹871.05 Cr, which is a combination of fresh issue of ₹353.40 Cr and offer for sale of ₹517.64 Cr.
- Nephrocare Health’s will open for subscription on 10 Dec 2025 and close on 12 Dec 2025. And the price band is set between ₹438- ₹460.
- Nephrocare Health’s allotment is likely to take place on 15 Dec 2025 and the shares are expected to be listed on BSE and NSE on 17 Dec 2025.
- Promoters currently hold 78.90%, which will come down to 71.49% after IPO listing.
- IPO proceeds will be used to open new dialysis clinics in India (₹129.11 crore), repay or prepay borrowings (₹136 crore), and meet general corporate needs.
- Kfin Technologies will be the registrar for Nephrocare Health.
Nephrocare Health IPO Dates
Here are some important dates for the upcoming IPO of Nephrocare Health.
| IPO Open Date | 10-Dec-25 |
| IPO Close Date | 12-Dec-25 |
| IPO Allotment Date | 15-Dec-25 |
| Initiation of Refunds | 16-Nov-25 |
| Demat Credits | 16-Nov-25 |
| Listing Date | 17-Nov-25 |
| Listing on | BSE, NSE |
Nephrocare Health IPO Reservation
For Nephrocare Health IPO, 35% has been reserved for retail investors.
| Investor Category | Shares Offered |
|---|---|
| QIB Investors | 50% |
| Retail Investors | 35% |
| NII (HNI) Investors | 15% |
Nephrocare Health IPO Lot Size
Retail investors can apply for a minimum of 1 lot, which includes 32 shares costing ₹14,720. Maximum investment allowed for retail investors is 13 lots, which totals 416 shares and costs ₹1,91,360.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 32 | ₹ 14,720 |
| Retail (Max) | 13 | 416 | ₹ 1,91,360 |
| S-HNI (Min) | 14 | 448 | ₹ 2,06,080 |
| S-HNI (Max) | 67 | 2,144 | ₹ 9,86,240 |
| B-HNI (Min) | 68 | 2,176 | ₹ 10,00,960 |
About Nephrocare Health IPO
Nephrocare Health Services, founded in 2010, is one of India’s largest dialysis care providers, offering a full range of services such as haemodialysis, home dialysis, mobile dialysis, and wellness support. The company also operates its own pharmacy network to support patient needs.
The company has centers in Philippines, Uzbekistan, and Nepal, and operates one of the world’s largest dialysis clinics in Uzbekistan. In India, it is present across 21 states and 4 union territories.
To expand its reach, Nephrocare partners with major hospital chains, including Max, Fortis Escorts, Care Hospitals, Wockhardt, Paras Healthcare, CMRI, Jehangir Hospital, and Ruby Hall Clinic, to run in-house dialysis centers.
Nephrocare Health Financial Performance
Nephrocare Health reported a PAT of ₹67.10 Cr as of 31 March 2025, and in FY24, it reported ₹35.13 Cr. Over the past three years, the company’s PAT has been growing continuously. All financial details are provided in the table below.
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets (₹Cr) | 996.46 | 806.02 | 666.23 |
| Total income (₹Cr) | 769.92 | 574.72 | 443.26 |
| PAT (₹Cr) | 67.1 | 35.13 | -11.79 |
| EBITDA (₹Cr) | 166.64 | 99.66 | 48.6 |
| Net Worth (₹Cr) | 594.21 | 423.55 | 384.73 |
| Reserves and Surplus (₹Cr) | 578.68 | 408.57 | 383.5 |
| Total Borrowing (₹Cr) | 225.8 | 243.37 | 196.21 |
| PAT Margin (%) | 8.88 | 6.21 | 2.70) |
| ROE (%) | 13.45 | 8.76 | -3 |
| ROCE (%) | 18.7 | 10.00 | 0.44 |
| Debt/Equity | 0.05 | 0.17 | 0.08 |
Nephrocare Health IPO Peer Comparison from RHP
Nephrocare Health has the lowest EPS compared to its peers. Higher EPS is always considered better. Below is a quick comparison of Nephrocare Health vs Narayana Health vs Dr. Lal Path Labs
| Company | EPS Diluted (₹) | P/E (x) |
|---|---|---|
| Nephrocare Health Services. | 8.01 | - |
| Narayana Health | 38.9 | 45.21 |
| Jupiter Life Line Hospitals | 29.47 | 51.1 |
| Rainbow Children Hospital | 23.84 | 56.84 |
| Dr. Agarwal's Healthcare | 2.78 | 179.42 |
| Dr. Lal Path Labs | 58.4 | 52.47 |
| Metropolis Healthcare | 28.15 | 69.48 |
| Vijaya Diagnostics | 13.92 | 73.14 |
Nephrocare Health Strengths and Risks
Knowing about the strengths and weaknesses of Nephrocare Health helps you make an informed decision.
- One of Asia’s largest dialysis providers based on treatment volume.
- Operates 447 centres, giving it strong nationwide coverage.
- Offers unique services such as holiday dialysis and mobile dialysis for patient convenience.
- Serves a large and growing patient base of over 33,000 people each year.
- Running and expanding dialysis centres requires heavy capital investment.
- Maintaining consistent quality across a large number of clinics can be challenging.
- Faces rising competition from hospitals and smaller regional dialysis providers.
- High operating costs could put pressure on long-term profitability.
FAQs on Nephrocare Health IPO GMP
What is Nephrocare Health GMP Today?
Nephrocare Health GMP today is ₹0
What are Nephrocare Health Expected Returns?
Nephrocare Health Expected Returns are 0%, as of 9th Dec, this may change in the coming days.
When will Nephrocare Health open and close?
Nephrocare Health’s will open for subscription on 10 Dec 2025 and close on 12 Dec 2025.
What is the lot size for Nephrocare Health?
Retail Investors can bid for a minimum of 1 lot, which includes 32 shares. And one lot will cost you ₹14,720.
What is the share allotment date for Nephrocare Health?
The allotment of shares is expected to be completed by 15 Dec 2025.
Who is the registrar of Nephrocare Health?
Kfin Technologies is the registrar for Nephrocare Health’s.
Is Nephrocare Health good to buy?
Nephrocare Health may attract investors due to its growing PAT and positive ROE & ROCE.
Happy investing and thank you for reading!
Disclaimer:
This website content is only for educational purposes, not investment advice. Before making any investment, it’s important to do your own research and be fully informed. Investing in the stock market includes risks, and you should carefully read the Risk Disclosure documents before proceeding. Please remember that past performance doesn’t guarantee future results, and due to market fluctuations, your investment goals may not always be achieved.
